Dualitas Therapeutics Launches With $65 Million Series A

Santa Monica – September 16, 2025 – Cooley advised Dualitas Therapeutics, a biotechnology company pioneering next-generation bispecific antibody therapies for immunology and inflammation, on its $65 million Series A financing, to advance a portfolio of next-generation bispecific antibodies, including lead programs DTX-103 in allergic disease and DTX-102 for autoimmune disease, and to accelerate the development of Dualitas’ proprietary DualScreen BsAb discovery engine. The round was co-led by Versant Ventures and Qiming Venture Partners USA, with additional participation from founding investor SV Health Investors and new strategic investors Chugai Venture Fund, Eli Lilly and Company, and Alexandria Venture Investments. 

Lawyers Sara Semnani, Noel Ripberger-Scheick, Sam Thompson, Michael Aridi Barake and Cameron Hajialiakbar led the Cooley team advising Dualitas, with support from paralegal Christy Fairlie and senior transactional quantitative analyst Jake Ironfield.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.